MAVEN’S MISSION

Infectious Disease Diagnostics: Proven Performance in the Field

Real-World Impact at Global Scale

Maven diagnostic technologies have enabled the deployment of over 5 million point-of-care tests for tropical and infectious diseases across Africa, Asia, and South America. These high-sensitivity assays—based on saliva, finger-prick blood, or swab samples—empower early diagnosis, timely treatment, and significantly improved health outcomes.

Validated Assays for Antibodies, Antigens, and Biomarkers

Our portfolio includes completed demonstrations of point-of-care diagnostics for:

• Tuberculosis (antibody and biomarker)

• Leprosy (antibody and biomarker)

• Schistosomiasis (antibody)

• Neurocysticercosis (antigen)

• Autoimmune diseases (e.g., Infliximab and anti-TNFα monitoring)

Several additional targets, such as Ebola, Anthrax, and PNH/aHUS (Eculizumab detection), are in near-final or ongoing field trials.

Science-Driven, Field-Tested

Each assay is optimized for use in basic lab or point-of-care (POC) settings—designed for low-resource environments without compromising accuracy or sensitivity. These tests provide rapid, actionable insights and are already helping frontline healthcare workers reduce disease burden through earlier intervention.

Pipeline and Long-Term Targets

Our development roadmap includes advanced diagnostic candidates for:

• Neisseria Meningitidis

These represent long-term goals currently undergoing early-stage validation and research.

Trusted Partners in Global Health

We collaborate with world-leading institutions to bring these diagnostics to life, including:

• Bill & Melinda Gates Foundation

• U.S. Centers for Disease Control and Prevention (CDC)

• Leiden University